Gold prices briefly hit record high over $3,500/oz on fiscal, tariff concerns
Cathie Wood’s ARK ETFs have made their latest market moves public, revealing a significant buy in Intellia Therapeutics Inc (NASDAQ:NTLA) and a continued sell-off of DraftKings Inc (NASDAQ:DKNG) shares on Friday, August 29, 2025. The trades indicate a clear strategic adjustment within ARK’s investment portfolio, as the firm adjusts its holdings in the biotech and entertainment sectors.
The largest transaction of the day was ARK’s purchase of 133,015 shares of Intellia Therapeutics Inc (NASDAQ:NTLA), amounting to a total dollar value of $1,542,974. This acquisition is part of a noticeable trend, as ARK has been consistently increasing its stake in the gene-editing company throughout the past week, signaling strong confidence in the stock’s future performance.
Conversely, ARK offloaded a total of 12,990 shares of DraftKings Inc (NASDAQ:DKNG) across three of its ETFs—ARKK, ARKW, and ARKF—totaling a dollar value of $626,507. This sale continues a pattern of reducing exposure to the online sports betting company, which has been seen in ARK’s trading behavior over the recent days. On Thursday, ARK sold 54,679 shares, and on Wednesday, the number was even more significant at 266,052 shares sold.
This strategic pivot suggests that Cathie Wood and her team are possibly reallocating resources from DraftKings to other sectors, notably biotechnology, where they seem to be doubling down. Intellia Therapeutics has been a major beneficiary of this shift, with ARK’s consistent buying indicating a bullish outlook on the company’s gene-editing technology.
Investors and market watchers will likely be keeping a close eye on these developments, as ARK’s trades can often influence market sentiment around the stocks they target. The transparency of ARK’s daily trade reports offers a unique insight into the investment strategies of one of the most closely followed fund managers in the industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.